KOD Earning Date, Earning Analysis and Earning Prediction

Quarterly Results

KOD Earnings Forecast

Looking ahead, KOD remains a focal point for investors seeking growth opportunities. Analyst forecasts for project quarter revenue of undefined and an EPS of -1.05.

However, recent estimate revisions provide additional context. Over the past three months, revenue estimates for FY2025 have been unchanged by 0%, while EPS estimates have been revised downward by -13.57%. For the upcoming , revenue estimates have been adjusted unchanged by 0%. These revisions correlate with a 0% change in stock price over the same period, suggesting potential buying opportunities for investors who believe in KOD long-term fundamentals.

The relationship between earnings forecast revisions and stock price movements is critical for investors. Positive revisions in revenue or EPS often signal strengthening fundamentals, making temporary price dips attractive entry points. Conversely, downward revisions may reflect short-term challenges.

RevenueEPS

Currency: USD

Revenue Estimate-:0

EPS Estimate-:0

—

Stock Price0

EPS Estimates for FY2025

No Change

0.00%

In Past 3 Month

Stock Price

Go Down

-13.57%

In Past 3 Month

Earnings Forecast

Revenue

EPS

Currency:

No data

Actual

Estimate

AI Analysis

Earnings Surprise Analysis

Revenue

EPS

AI Analysis

Earnings Reaction

The chart below shows how KOD performed 10 days before and after its earnings report, based on data from the past quarters. Typically, KOD sees a 1.12% change in stock price 10 days leading up to the earnings, and a -3.81% change 10 days following the report. On the earnings day itself, the stock moves by -4.56%. This data can give you a slight idea of what to expect for the next quarter's release.

For example, in SEP/2025, the stock changed 3.39% on the day following the earnings release and then changed by 21.78% over the next 10 days. These patterns provide investors with valuable insights into potential price movements and help inform trading strategies around earnings events.

People Also Watch

Frequently Asked Questions

What were the key highlights of KOD's latest earnings report for ?

KOD reported its earnings on 2026-03-23, showcasing a revenue of against an estimate of , resulting in a 0% surprise. The EPS was 0, surpassing the expected -1.02 by 0%. The stock experienced a 0% price change on the earnings day and a 0% change over the next five days, reflecting market reactions to the results.

How did KOD's stock price react after the earnings release?

Following KOD's earnings announcement on 2026-03-23, the stock price moved by 0% on the day of the release. Over the subsequent five days, it saw a 0% change. Historically, KOD's stock price tends to shift by an average of 1.12% in the 10 days leading up to earnings and -3.81% in the 10 days following, providing insight into potential market.

What are the revenue and EPS estimates for KOD for ?

For , analysts estimate KOD's annual revenue to reach undefined, while the EPS is projected at -1.05. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

How does KOD's stock price correlate with earnings forecast revisions?

The correlation between KOD's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were unchanged by 0%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

What should investors expect from KOD's next earnings report?

Based on historical trends, KOD's stock price typically moves by 1.12% in the 10 days before its earnings and -3.81% in the 10 days after. For the upcoming earnings, analysts expect an EPS of -1.05 and revenue of undefined.

What is the sentiment in Kodiak Sciences Inc (KOD) Q4 2023 Earnings Call Summary?

The earnings call highlights strong efficacy and safety results for multiple studies, including tarcocimab and KSI-501, which are positive indicators. Management's confidence in advancing from Phase 1 to Phase 3 trials underscores potential growth. The Q&A reveals optimism despite some uncertainties, and there is alignment with the FDA. The positive sentiment from product development and strategic planning outweighs the lack of detailed guidance, suggesting a positive stock price movement.